Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy

[Image: see text] Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become standard of care for certain types of cancers. However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies. Combination therapy strategies...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:ACS Med Chem Lett
Prif Awduron: Zhang, Hongjun, Liu, Kun, Pu, Qinglin, Achab, Abdelghani, Ardolino, Michael J., Cheng, Mangeng, Deng, Yongqi, Doty, Amy C., Ferguson, Heidi, Fradera, Xavier, Knemeyer, Ian, Kurukulasuriya, Ravi, Lam, Yu-hong, Lesburg, Charles A., Martinot, Theodore A., McGowan, Meredeth A., Miller, J. Richard, Otte, Karin, Biju, Purakattle J., Sciammetta, Nunzio, Solban, Nicolas, Yu, Wensheng, Zhou, Hua, Wang, Xiao, Bennett, David Jonathan, Han, Yongxin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Chemical Society 2019
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6862341/
https://ncbi.nlm.nih.gov/pubmed/31749906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00344
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg